AEON Biopharma announced expanded primary structure and preliminary disulfide bond data for its biosimilar candidate, ABP-450, demonstrating high molecular similarity to BOTOX. This positive data supports the development pathway for ABP-450 and could lead to increased investor confidence in its market potential.
AEON Biopharma released new data on its biosimilar candidate, ABP-450, showing strong molecular similarity to BOTOX. This is a crucial step in the biosimilar development process, as demonstrating high similarity is required for regulatory approval. For AEON, this news is a significant positive, potentially de-risking the development of ABP-450 and increasing its chances of market entry, which could lead to a short-term positive stock reaction. Long-term, successful market entry would provide a new revenue stream for AEON. For AbbVie (ABBV), the owner of BOTOX, the news introduces a potential future competitor, though the impact is not immediate given the development stage. Traders should watch for further FDA feedback and clinical trial results as key catalysts.